Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-9-14
pubmed:abstractText
Rapid genetic screening for cytochrome P450 (CYP) 2C9 variants may play a role in improving the efficacy and safety of warfarin in individuals with CYP2C9 variants. The feasibility of prospective CYP2C9 model-based warfarin dosing has not yet been assessed.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-10073515, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-10961881, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-11157641, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-11503010, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-11588061, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-11926893, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-12406644, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-12496751, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-12668507, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-12866628, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-15148533, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-15284536, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-8873220, http://linkedlifedata.com/resource/pubmed/commentcorrection/16160068-9005747
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1539-4182
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
137-45
pubmed:dateRevised
2010-3-23
pubmed:meshHeading
pubmed-meshheading:16160068-Aged, pubmed-meshheading:16160068-Anticoagulants, pubmed-meshheading:16160068-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:16160068-Blood Coagulation, pubmed-meshheading:16160068-DNA, pubmed-meshheading:16160068-DNA Probes, pubmed-meshheading:16160068-Dose-Response Relationship, Drug, pubmed-meshheading:16160068-Female, pubmed-meshheading:16160068-Follow-Up Studies, pubmed-meshheading:16160068-Genotype, pubmed-meshheading:16160068-Humans, pubmed-meshheading:16160068-Male, pubmed-meshheading:16160068-Models, Genetic, pubmed-meshheading:16160068-Pilot Projects, pubmed-meshheading:16160068-Point Mutation, pubmed-meshheading:16160068-Prospective Studies, pubmed-meshheading:16160068-Reproducibility of Results, pubmed-meshheading:16160068-Sensitivity and Specificity, pubmed-meshheading:16160068-Single-Blind Method, pubmed-meshheading:16160068-Thromboembolism, pubmed-meshheading:16160068-Warfarin
pubmed:year
2005
pubmed:articleTitle
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
pubmed:affiliation
Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449, USA. wilke.russell@mcrf.mfldclin.edu
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't